{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:58:49Z","timestamp":1786118329680,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd013614","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000}}],"reference-count":507,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013614.pub2","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T07:02:49Z","timestamp":1739430169000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Giovanni","family":"Cagnotto","sequence":"additional","affiliation":[{"name":"Clinical Sciences Malm\u00f6; Lund University; Malm\u00f6 Sweden"},{"name":"Rheumatology; Sk\u00e5ne University Hospital; Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bruschettini","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Paediatrics; Lund University, Sk\u00e5ne University Hospital; Lund Sweden"},{"name":"Cochrane Sweden, Department of Research, Development, Education and Innovation; Lund University, Sk\u00e5ne University Hospital; Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Str\u00f3\u017cyk","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; Medical University of Warsaw; Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Scir\u00e8","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Milano-Bicocca; Milan Italy"},{"name":"Rheumatology Unit; IRCCS San Gerardo dei Tintori Foundation; Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Compagno","sequence":"additional","affiliation":[{"name":"Clinical Sciences Malm\u00f6; Lund University; Malm\u00f6 Sweden"},{"name":"Rheumatology; Sk\u00e5ne University Hospital; Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1227-36","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0002|cit2","first-page":"869-76","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1038-43","DOI":"10.1136\/ard.2005.045658","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/ard.2005.040196","article-title":"Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0006|cit6","first-page":"2254-9","article-title":"Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis","volume":"33","author":"Kavanaugh","year":"2006","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0008|cit8","unstructured":"A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis https:\/\/clinicaltrials.gov\/show\/NCT00051623 2003"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0009|cit9","first-page":"783","article-title":"Rapid and persistent improvement of psoriasis in patients with active psoriatic arthritis treated with infliximab: 24-week results of the impact 2 trial. Abstract P028 European Congress on Psoriasis 2004","volume":"18","author":"Papp","year":"2004","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"Van der Heijde","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2017-eular.5398","article-title":"Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PSA patients with active enthesitis-results from the Enthesial Clearance in Psoriatic Arthritis (ECLIPSA) study","volume":"76","author":"Araujo","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the Enthesial Clearance In Psoriatic Arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10067-009-1340-7","article-title":"Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs","volume":"29","author":"Atteno","year":"2010","journal-title":"Clinical Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0015|cit15","unstructured":"A randomized, multicenter, international, open-label study of infliximab plus methotrexate versus methotrexate (MTX) alone for the treatment of MTX na\u00efve subjects with Active Psoriatic Arthritis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2005-002189-12-SI 2005"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0016|cit16","first-page":"1256","article-title":"Infliximab plus methotrexate significantly improves rates of remission for methotrexate nave psoriatic arthritis (PsA) patients compared to methotrexate alone: the RESPOND trial","volume":"60","author":"Raffayova","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0017|cit17","first-page":"1780","article-title":"Infliximab plus methotrexate significantly improves synovitis and psoriatic lesions in methotrexate nave psoriatic arthritis (PsA) patients: results of the RESPOND trial","volume":"60","author":"Raffayova","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0018|cit18","unstructured":"Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Na\u00efve Disease (RESPOND) (Study P04422) https:\/\/clinicaltrials.gov\/show\/NCT00367237 2006"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0394632017714695","article-title":"Anti-TNF-alpha effects on anemia in rheumatoid and psoriatic arthritis","volume":"30","author":"Corrado","year":"2017","journal-title":"International Journal of Immunopathology and Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0020|cit20","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0021|cit21","unstructured":"Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00646178 2008"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0022|cit22","first-page":"ii223","article-title":"Treatment with biological agents improves endothelial and coronary artery function in parallel with left ventricular deformation and twisting in patients with psoriasis","volume":"14","author":"Ikonomidis","year":"2013","journal-title":"European Heart Journal Cardiovascular Imaging"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0023|cit23","first-page":"i19","article-title":"Golimumab, a new, human, TNF \u03b1 antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo controlled go-reveal study","volume":"49","author":"Gladman","year":"2010","journal-title":"Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0024|cit24","first-page":"1327","article-title":"Golimumab, a new, human, TNF alpha antibody, administered SC every 4weeks in PsA patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study","volume":"37","author":"Gladman","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"s3","key":"10.1002\/14651858.CD013614.pub2-BIB0025|cit25","first-page":"35","article-title":"Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled go-reveal study","volume":"40","author":"Gladman","year":"2010","journal-title":"Internal Medicine Journal"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0026|cit26","first-page":"1326","article-title":"Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 Week results from the GO-REVEAL study","volume":"37","author":"Gladman","year":"2010","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0027|cit27","first-page":"158","article-title":"Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the go-reveal study","volume":"13","author":"Gladman","year":"2010","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0028|cit28","first-page":"1736","article-title":"Golimumab treatment inhibits progression in joint damage in patients with psoriatic arthritis regardless of baseline disease severity","volume":"39","author":"Kavanaugh","year":"2012","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0029|cit29","first-page":"iii69","article-title":"Golimumab treatment inhibits progression of joint damage in patients with psoriatic arthritis regardless of baseline disease severity","volume":"51","author":"Kavanaugh","year":"2012","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0030|cit30","first-page":"i56","article-title":"Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week health-related quality of life, physical function and health economic results of the randomized, placebo-controlled go-reveal study","volume":"49","author":"Kavanaugh","year":"2010","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0031|cit31","first-page":"1261","article-title":"Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-Week health-related quality of life, physical function and health economic results of the randomized, placebo-controlled GO-REVEAL study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0032|cit32","article-title":"Golimumab treatment inhibits progression in joint damage in patients with psoriatic arthritis regardless of baseline disease severity","volume":"63","author":"Kavanaugh","year":"2011","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0033|cit33","first-page":"iii90","article-title":"Early and sustained remission associated with normalized physical function, health-related quality of life and significantly improved productivity in patients with active psoriatic arthritis treated with golimumab: 2-year data from phase iii GO-REVEAL trial","volume":"51","author":"Kavanaugh","year":"2012","journal-title":"Rheumatology (United Kingdom)"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0034|cit34","first-page":"1736","article-title":"Early and sustained remission associated with normalized physical function, health-related quality of life & significantly improved productivity in patients with active psoriatic arthritis treated with golimumab: 2-year data from phase III GO-REVEAL trial","volume":"39","author":"Kavanaugh","year":"2012","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"A135","DOI":"10.1016\/j.jval.2011.02.749","article-title":"Early and sustained remission associated with normalized physical function and health-related quality of life and significantly improved productivity in patients with active psoriatic arthritis treated with golimumab: Two year data from the phase III go-reveal clinical trial","volume":"14","author":"Kavanaugh","year":"2011","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0036|cit36","first-page":"iii141","article-title":"High level responses in psoriatic arthritis patients treated with golimumab: results from week 104 of the go-reveal study","volume":"50","author":"Kavanaugh","year":"2011","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/annrheumdis-2014-eular.2254","article-title":"Impact of persistent minimal disease activity on long-term outcomes in psoriatic arthritis: results from 5 years of the long term extension of a randomized, placebo-controlled, study","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"976-86","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0039|cit39","first-page":"246","article-title":"Early and sustained remission associated with normalized physical function and health-related quality of life and significantly improved productivity in patients with active psoriatic arthritis treated with golimumab: GO-REVEAL 2-year data","volume":"17","author":"Kavanaugh","year":"2011","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/acr.22044","article-title":"Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kavanaugh","year":"2013","journal-title":"Arthritis Care & Research"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5\u2005years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2012-202035","article-title":"Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0043|cit43","first-page":"S147","article-title":"Impact of persistent minimal disease activity on long-term outcomes in psoriatic arthritis: results from 5 years of the long term extension of a randomized, placebo-controlled, study","volume":"65","author":"Kavanaugh","year":"2013","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0044|cit44","first-page":"A56","article-title":"Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis: 52-week efficacy and safety results of the go-reveal study","volume":"39","author":"Kavanaugh","year":"2009","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-Week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0046|cit46","first-page":"90","article-title":"Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL)","volume":"89","author":"Kavanaugh","year":"2012","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0047|cit47","first-page":"iii143","article-title":"Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the go-reveal study","volume":"50","author":"Kavanaugh","year":"2011","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0048|cit48","first-page":"iii23","article-title":"Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104 week results from the GO-REVEAL study","volume":"51","author":"Kavanaugh","year":"2012","journal-title":"Rheumatology (United Kingdom)"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0049|cit49","first-page":"1735","article-title":"Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104 week results from the GO-REVEAL study","volume":"39","author":"Kavanaugh","year":"2012","journal-title":"Journal of Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD013614.pub2-BIB0050|cit50","first-page":"3861","article-title":"Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GO-REVEAL study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0051|cit51","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-202035","article-title":"5 Year safety, efficacy, and radiographic data in patients with active psoriatic arthritis treated with golimumab: long-term extension results of the randomized, placebo-controlled study GO-REVEAL","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S938","DOI":"10.1002\/art.34436","article-title":"5 Year safety, efficacy, and radiographic data in patients with active psoriatic arthritis treated with golimumab: results from the long-term extension of a randomized, placebo-controlled study","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0053|cit53","first-page":"1943","article-title":"Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104 week results from the GO-REVEAL study","volume":"62","author":"Kavanaugh","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"AB199","DOI":"10.1016\/j.jaad.2012.12.822","article-title":"Effects of golimumab on the dermatologic manifestations of psoriatic arthritis: 5-year results from the long-term extension of the randomized, placebo-controlled, GO-REVEAL study","volume":"68","author":"Krueger","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0056|cit56","first-page":"i58","article-title":"Golimumab administered every four weeks as a subcutaneous injection in psoriatic arthritis: nail, enthesitis, and dactylitis response in the randomized, placebo-controlled, GO-REVEAL study","volume":"48","author":"McInnes","year":"2009","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0057|cit57","first-page":"i7","article-title":"Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis: 52-week efficacy and safety results of the GO-REVEAL study","volume":"48","author":"McInnes","year":"2009","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0058|cit58","unstructured":"A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis https:\/\/clinicaltrials.gov\/show\/NCT00265096 2005"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0059|cit59","first-page":"1401","article-title":"Assessing HRQoL burden of disease and comparison to the U.S. population in psoriatic arthritis patients treated with golimumab: results from the GO-REVEAL trial","volume":"60","author":"Raju","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0060|cit60","first-page":"994","article-title":"Intravenous golimumab in adult patients with active psoriatic arthritis: efficacy and safety through 1 year","volume":"45","author":"Husni","year":"2018","journal-title":"Journal of Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"A538","DOI":"10.1016\/j.jval.2017.08.788","article-title":"Impact of golimumab, an anti-TNFa monoclonal antibody, on health related quality of life (HRQOL) and work productivity in patients with active psoriatic arthritis: 24-week results of the phase III GO-VIBRANT trial","volume":"20","author":"Husni","year":"2017","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0062|cit62","article-title":"Effects of intravenous golimumab, an anti-TNF\u03b1 monoclonal antibody, on mental and physical functioning and health-related quality of life in active psoriatic arthritis: 24-week results of a phase 3 trial","volume":"69","author":"Husni","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/acr.23905","article-title":"Efficacy and safety of intravenous golimumab through 1 year in patients with active psoriatic arthritis","volume":"72","author":"Husni","year":"2019","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2019-eular.1282","article-title":"Clinically meaningful improvement in skin and nail psoriasis in bio-naive active psoriatic arthritis patients treated with intravenous golimumab: Results through week 52 from a phase-3 study","volume":"78","author":"Husni","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0065|cit65","first-page":"2862","article-title":"Clinically meaningful improvement in skin and nail psoriasis in bio-na\u00efve active psoriatic arthritis patients treated with intravenous golimumab: Results through week 24 from a phase 3 study","volume":"70","author":"Husni","year":"2018","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0066|cit66","first-page":"2840","article-title":"Fatigue in psoriatic arthritis patients treated with intravenous golimumab: Early improvement is associated with week 24 outcomes in Acr 20 50, and health-related quality of life","volume":"70","author":"Kavanaugh","year":"2018","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT Study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3899\/jrheum.180681","article-title":"Radiographic progression inhibition with intravenous golimumab in psoriatic arthritis: Week 24 results of a Phase III, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kavanaugh","year":"2019","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0069|cit69","first-page":"S67","article-title":"Clinically meaningful improvement in skin and nail psoriasis in bio-na\u00cfve active psoriatic arthritis patients treated with intravenous golimumab: Results through week 24 of the GO-VIBRANT study","volume":"25","author":"Mease","year":"2019","journal-title":"Journal of Clinical Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0070|cit70","first-page":"S67","article-title":"Inhibition of radiographic progression and correlation with changes in composite disease activity indices in patients with active psoriatic arthritis treated with intravenous golimumab, as measured in a phase III trial","volume":"25","author":"Mease","year":"2019","journal-title":"Journal of Clinical Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/annrheumdis-2018-eular.1766","article-title":"Clinically meaningful improvement in skin and nail psoriasis in bio-na\u00efve active psoriatic arthritis patients treated with intravenous golimumab: results through week 24 of the GO-VIBRANT study","volume":"77","author":"Mease","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/annrheumdis-2019-eular.180","article-title":"Inhibition of radiographic progression was achieved with intravenous golimumab in active PsA patients regardless of changes in composite indices of disease activity in a phase III trial","volume":"78","author":"Mease","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0073|cit73","unstructured":"A Study of Golimumab in Participants With Active Psoriatic Arthritis https:\/\/clinicaltrials.gov\/show\/NCT02181673 2014"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0074|cit74","unstructured":"Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-004477-32-AT 2016"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0075|cit75","first-page":"i101","article-title":"Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study","volume":"60 (Suppl 1)","author":"Gottlieb","year":"2021","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2020-eular.4736","article-title":"Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study","volume":"79 (Suppl 1)","author":"Gottlieb","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"AB92","DOI":"10.1016\/j.jaad.2021.06.388","article-title":"Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with moderate-to-severe plaque psoriasis: results from the EXCEED study","volume":"85","author":"Gottlieb","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/annrheumdis-2021-eular.1562","article-title":"Effect of secukinumab versus adalimumab on acr core components and health-related quality of life in patients with psoriatic arthritis: results from the EXCEED study","volume":"80 (Suppl 1)","author":"Goupille","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013614.pub2-BIB0080|cit80","first-page":"3808","article-title":"Secukinumab treatment provides sustained resolution of enthesitis at individual joints through 52 weeks in a phase 3b, double-blind, randomized, active-controlled study","volume":"73","author":"Kaeley","year":"2021","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2021-eular.463","article-title":"Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of EXCEED","volume":"80 (Suppl 1)","author":"Kaeley","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/rheumatology\/kead181","article-title":"Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study","volume":"63","author":"Kaeley","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"AB542022","DOI":"10.1016\/j.jaad.2022.06.251","article-title":"Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of EXCEED","volume":"87","author":"Kaeley","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2020-eular.4129","article-title":"Secukinumab versus adalimumab head-to-head comparison in biologic-naive patients with active psoriatic arthritis through 52-weeks (EXCEED): a randomised, double-blind, phase-3b study","volume":"79 (Suppl 1)","author":"McInnes","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10235","key":"10.1002\/14651858.CD013614.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0086|cit86","unstructured":"Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis https:\/\/clinicaltrials.gov\/show\/NCT02745080 2016"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013614.pub2-BIB0087|cit87","first-page":"465","article-title":"Impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis: results from a phase 3 trial","volume":"73","author":"Bessette","year":"2021","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0088|cit88","unstructured":"A study comparing ABT-494 to placebo and to adalimumab in subjects with psoriatic arthritis who have an inadequate response to at least one non-biologic disease modifying anti-rheumatic drug http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-004130-24-BE 2017"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0089|cit89","first-page":"77","article-title":"Impact of patient characteristics, including sex, on the efficacy of upadacitinib compared with adalimumab in patients with psoriatic arthritis","volume":"50","author":"Eder","year":"2023","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/annrheumdis-2022-eular.1371","article-title":"Association between clinically meaningful improvements in patient-reported outcomes and stringent measures of disease activity in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from a phase 3 trial","volume":"81","author":"Gossec","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl9","key":"10.1002\/14651858.CD013614.pub2-BIB0091|cit91","first-page":"3986","article-title":"Association between clinically meaningful improvements in patient-reported outcomes and stringent measures of disease activity in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from a phase 3 trial","volume":"73","author":"Gossec","year":"2021","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0092|cit92","first-page":"60","article-title":"Long-term safety and effectiveness of upadacitinib in patients with psoriatic arthritis: results at 56 weeks from the SELECT-PsA 1 study","volume":"24","author":"Kishimoto","year":"2021","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0093|cit93","first-page":"34","article-title":"Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with PsA and inadequate response to non-biologic DMARDs (SELECT-PsA-1)","volume":"23","author":"Kishimoto","year":"2020","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"Suppl1","key":"10.1002\/14651858.CD013614.pub2-BIB0094|cit94","first-page":"i92","article-title":"Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active PsA and inadequate response to non-biologic DMARDs (SELECT-PSA-1): a double-blind, randomised controlled phase III trial","volume":"60","author":"McInnes","year":"2021","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0095|cit95","first-page":"12","article-title":"Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-1): a double blind, randomized controlled phase 3 trial","volume":"79","author":"McInnes","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0096|cit96","first-page":"4070","article-title":"Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying anti-rheumatic drugs: a double-blind, randomized controlled phase 3 trial","volume":"72","author":"McInnes","year":"2020","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/annrheumdis-2021-eular.397","article-title":"Long-term safety and effectiveness of upadacitinib in patients with psoriatic arthritis: results at 56 weeks from the Select-PsA 1 study","volume":"80","author":"McInnes","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"13","key":"10.1002\/14651858.CD013614.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0100|cit100","unstructured":"A study comparing upadacitinib (ABT-494) to placebo and to adalimumab in participants with psoriatic arthritis who have an inadequate response to at least one non-biologic disease modifying anti-rheumatic drug https:\/\/clinicaltrials.gov\/show\/NCT03104400 2017"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0101|cit101","first-page":"2697","article-title":"Improvement in patient-reported outcomes in patients with psoriatic arthritis with inadequate response to non-biologic DMARDs treated with upadacitinib versus placebo or adalimumab: results from a Phase 3 study","volume":"-","author":"Strand","year":"2020","journal-title":"Arthritis & Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40744-021-00379-9","article-title":"Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT-PsA 1","volume":"8","author":"Strand","year":"2021","journal-title":"Rheumatology & Therapy"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0103|cit103","unstructured":"A study to test the efficacy and safety of bimekizumab in the treatment of subjects with active psoriatic arthritis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002804-29\/HU 2019 TrialID=EUCTR2017 002322-20-CZ"},{"issue":"Suppl 271","key":"10.1002\/14651858.CD013614.pub2-BIB0104|cit104","first-page":"24S","article-title":"Achievement of increasingly stringent clinical disease control criteria was associated with greater improvements in physical function, pain and fatigue in patients with active psoriatic arthritis: 52-Week results from BE OPTIMAL, a phase 3 randomised, placebo-controlled study","volume":"152","author":"Kristensen","year":"2023","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0105|cit105","first-page":"334","article-title":"Bimekizumab in biologic DMARD-Na\u00efve patients with psoriatic arthritis: 24 week efficacy & safety from BE OPTIMAL","volume":"26","author":"McInnes","year":"2023","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2022-eular.5016","article-title":"Bimekizumab in bDMARD-naive patients with psoriatic arthritis: 24 week efficacy & safety from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study","volume":"81","author":"McInnes","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"ii105","DOI":"10.1093\/rheumatology\/kead104.212","article-title":"Bimekizumab in bDMARD-naive patients with active psoriatic arthritis: improvements in PSARC over 24 weeks in the phase 3 BE OPTIMAL trial","volume":"62","author":"McInnes","year":"2023","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0108|cit108","first-page":"78","article-title":"Bimekizumab efficacy and safety in biologic bDMARD-na\u00efve patients with psoriatic arthritis was consistent with or without methotrexate: 52-week results from the phase 3 active-reference study BE OPTIMAL","volume":"52","author":"McInnes","year":"2023","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2023-eular.1694","article-title":"Bimekizumab efficacy and safety in biologic-naive patients with psoriatic arthritis was consistent with or without methotrexate: 52-week results from the phase 3 active-reference study BE OPTIMAL","volume":"82","author":"McInnes","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"AB1282023","DOI":"10.1016\/j.jaad.2023.07.514","article-title":"Bimekizumab in bDMARD-na\u00efve patients with psoriatic arthritis and skin involvement: analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo- controlled, active reference study","volume":"89","author":"Merola","year":"2023","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0112|cit112","first-page":"26","article-title":"Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from a phase 3, randomized, placebo-controlled, active reference study","volume":"53","author":"Ostor","year":"2023","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0113|cit113","first-page":"4533-6","article-title":"Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from a phase 3, randomized, placebo-controlled, active reference study","volume":"74","author":"Ritchlin","year":"2022","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/ard-2023-224431","article-title":"Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study","volume":"82","author":"Ritchlin","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2023-eular.1667","article-title":"Bimekizumab mantained efficacy responses through 52 weeks in biologic disease modifying antirheumatic drug-naive patients with psoriatic arthritis who were responders at week 16: results from BE OPTIMAL, a phase 3, active-reference study","volume":"82","author":"Tillett","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9227","key":"10.1002\/14651858.CD013614.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0117|cit117","first-page":"712-721","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"Journal of Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3899\/jrheum.091093","article-title":"Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis","volume":"37","author":"Mease","year":"2010","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0120|cit120","unstructured":"Double-blind, randomized, placebo-controlled phase 3 study of etanercept in the treatment of psoriatic arthritis and psoriasis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00317499 2006"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","article-title":"Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial","volume":"66","author":"Gladman","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis & Rheumatism"},{"issue":"Abstract-Band","key":"10.1002\/14651858.CD013614.pub2-BIB0123|cit123","first-page":"86","article-title":"Efficacy and tolerability of Adalimumab in patients with psoriasis-arthritis (PsA): results of the ADEPT study over 48 weeks","volume":"101","author":"Manger","year":"2006","journal-title":"Medizinische Klinik"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0124|cit124","unstructured":"Mease P Gladman D Ritchlin C Weinberg M Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial. Abstract P2865 American Academy of Dermatology 64th Annual Meeting AB214"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0125|cit125","unstructured":"Mease P Sharp J Ory P Gladman D Ritchlin C Choy E Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: results from ADEPT. Abstract P06.12 14th Congress of the European Academy of Dermatology and Venereology, London, UK; 12 to 15 October 2005 2005 163"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"702-9","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0128|cit128","unstructured":"Study of the safety and efficacy of the human anti-TNF monoclonal antibody adalimumab in subjects with moderately to severely active psoriatic arthritis https:\/\/clinicaltrials.gov\/show\/NCT00646386 2008"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1836-7","DOI":"10.1136\/annrheumdis-2019-eular.765","article-title":"Achievement of PASDAS low disease activity and very low disease activity in patients with psoriatic arthritis treated with certolizumab pegol over 4 years and the overlap with DAPSA and MDA disease activity targets","volume":"78","author":"Coates","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0130|cit130","first-page":"iii104","article-title":"Efficacy and safety of certolizumab pegol over four years in psoriatic arthritis patients with and without concomitant use of DMARDs","volume":"57","author":"Cooper","year":"2018","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2015-eular.1847","article-title":"Improvements in extra-articular manifestations of psoriatic arthritis over 96 weeks of certolizumab pegol treatment","volume":"74","author":"FitzGerald","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"AB255","DOI":"10.1016\/j.jaad.2016.02.990","article-title":"Improvements in extraarticular manifestations of psoriatic arthritis over 96-weeks of certolizumab pegol treatment","volume":"74","author":"FitzGerald","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"AB64","DOI":"10.1016\/j.jaad.2017.04.265","article-title":"Certolizumab pegol is associated with long-term improvements in extra-articular manifestations of psoriatic arthritis over 4-years of treatment","volume":"76","author":"FitzGerald","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"A569","DOI":"10.1016\/j.jval.2013.08.1524","article-title":"Long-term maintenance of improvements in multiple facets of psoriatic arthritis with certolizumab pegol: 48-week patient-reported outcome results of the Rapid-PsA study","volume":"16","author":"Gladman","year":"2013","journal-title":"Value in Health"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"A227","DOI":"10.1016\/j.jval.2013.03.1151","article-title":"Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients: 24-week patient reported outcome results of a phase 3 double blind randomized placebo controlled study","volume":"16","author":"Gladman","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0136|cit136","first-page":"i163","article-title":"Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III double-blind randomized placebo-controlled study","volume":"52","author":"Gladman","year":"2013","journal-title":"Rheumatology (United Kingdom)"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/acr.22256","article-title":"Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study","volume":"66","author":"Gladman","year":"2014","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0138|cit138","doi-asserted-by":"crossref","unstructured":"Gladman D Fleischmann R Coteur G Woltering F Mease PJ Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients with and without prior anti-TNF exposure: 24-week patient-reported outcome results of Rapid-PSA study Annals of the Rheumatic Diseases 2013","DOI":"10.1136\/annrheumdis-2013-eular.1985"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"A594","DOI":"10.1016\/j.jval.2016.09.1426","article-title":"Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the RAPID-PsA study","volume":"19","author":"Gladman","year":"2016","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2017-eular.1654","article-title":"Certolizumab pegol is associated with long-term improvements in patient-reported outcomes in psoriatic arthritis: 4-year outcomes from the Rapid-PsA study","volume":"76","author":"Gladman","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0141|cit141","article-title":"Long-term improvements with certolizumab pegol in joints and extra-articular manifestations of psoriatic arthritis in patients with and without prior anti-TNF exposure","volume":"67","author":"Gladman","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"A228","DOI":"10.1016\/j.jval.2013.03.1158","article-title":"Improvements in productivity at paid work and within household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double blind randomized placebo-controlled study","volume":"16","author":"Kavanaugh","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0143|cit143","first-page":"i163","article-title":"Improvements in productivity at paid work and within household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase iii double-blind randomized placebo-controlled trial","volume":"52","author":"Kavanaugh","year":"2013","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0144|cit144","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.2001","article-title":"Improvements in productivity at paid work and within household, and increased participation in daily activities after 24 weeks of certolizumab pegol in patients with psoriatic arthritis: Results of rapid-PSA study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"A545","DOI":"10.1016\/j.jval.2016.09.1151","article-title":"Long-term improvements in workplace and household productivity and social participation over 4 years of certolizumab pegol treatment in patients with psoriatic arthritis, with and without prior anti-TNF exposure","volume":"19","author":"Kavanaugh","year":"2016","journal-title":"Value in Health"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0146|cit146","first-page":"A570","article-title":"Sustained improvements in productivity at paid work and within household, and increased participation in daily activities over time with certolizumab pegol in patients with psoriatic arthritis: 48-week results from the RAPID-PsA study","volume":"16","author":"Kavanaugh","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0147|cit147","first-page":"S140","article-title":"Reduction of disease burden on workplace and household productivity in psoriatic arthritis over 48 weeks of treatment with certolizumab pegol","volume":"65","author":"Kavanaugh","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/annrheumdis-2014-205198","article-title":"Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24\u2005weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled trial","volume":"74","author":"Kavanaugh","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"A387","DOI":"10.1016\/j.jval.2014.08.2654","article-title":"Sustained improvements in workplace and household productivity and social participation with certolizumab pegol over 96 weeks in patients with psoriatic arthritis","volume":"17","author":"Kavanaugh","year":"2014","journal-title":"Value in Health"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"AB251","DOI":"10.1016\/j.jaad.2017.04.975","article-title":"The effect of certolizumab pegol on skin manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-TNF exposure","volume":"76","author":"Khraishi","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0151|cit151","first-page":"2164","article-title":"The effect of certolizumab pegol on skin manifestations of psoriatic arthritis over 4 years of treatment","volume":"68","author":"Khraishi","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/annrheumdis-2015-eular.1840","article-title":"Sustained improvements in skin outcomes following certolizumab pegol treatment of psoriatic arthritis patients with prior anti-TNF exposure or severe skin involvement at baseline","volume":"74","author":"Khraishi","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"e000119","DOI":"10.1136\/rmdopen-2015-000119","article-title":"Effect of certolizumab pegol over 96\u2005weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0154|cit154","first-page":"i162","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis with or without prior anti-TNF exposure: 24-week results of a phase iii double-blind randomized placebo-controlled study","volume":"52","author":"Mease","year":"2013","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0155|cit155","first-page":"S237","article-title":"Long-term safety and efficacy of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure","volume":"66","author":"Mease","year":"2014","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0156|cit156","first-page":"S1107","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis with and without prior anti-TNF exposure: 24 week results of a phase 3 double-blind randomized placebo-controlled study","volume":"64","author":"Mease","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"AB232","DOI":"10.1016\/j.jaad.2015.02.936","article-title":"Effect of certolizumab pegol on dermatologic outcomes over 96 weeks in patients with psoriatic arthritis","volume":"72","author":"Mease","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0158|cit158","first-page":"1447","article-title":"Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure","volume":"41","author":"Mease","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0159|cit159","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (rapid-PSA)","volume":"71","author":"Mease","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"48-55","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"A684","DOI":"10.1136\/annrheumdis-2013-eular.2023","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis from the rapid-PSA study: Impact of baseline skin involvement and prior anti-TNF therapy","volume":"72","author":"Mease","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0162|cit162","first-page":"786","article-title":"Long-term safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without prior anti-tumor necrosis factor exposure: 96-week outcomes of the rapid-PsA trial","volume":"32","author":"Mease","year":"2014","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0163|cit163","first-page":"608","article-title":"Certolizumab pegol for the treatment of psoriatic arthritis: 4-year outcomes from the RAPID-PsA trial","volume":"75","author":"Mease","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/annrheumdis-2016-eular.3205","article-title":"Improvements in joint outcomes of psoriatic arthritis over 4 years of treatment with certolizumab pegol in patients with and without prior anti-TNF exposure","volume":"75","author":"Mease","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1136\/annrheumdis-2014-eular.1652","article-title":"Long-term safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without prior anti-tumor necrosis factor exposure: 96-week outcomes from the RAPID-PSA trial","volume":"73","author":"Mease","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"i137","DOI":"10.1093\/rheumatology\/keu115.004","article-title":"Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure","volume":"53","author":"Mease","year":"2014","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0167|cit167","first-page":"S132","article-title":"Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure","volume":"65","author":"Mease","year":"2013","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0168|cit168","unstructured":"Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis https:\/\/clinicaltrials.gov\/show\/NCT01087788 2010"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"e000582","DOI":"10.1136\/rmdopen-2017-000582","article-title":"4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis","volume":"4","author":"Van Der Heijde","year":"2018","journal-title":"RMD Open"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"rmdopen","DOI":"10.1136\/rmdopen-2017-000582","article-title":"Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis","volume":"4","author":"Van Der Heijde","year":"2018","journal-title":"RMD Open"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2017-eular.1961","article-title":"The effect of certolizumab pegol on radiographic progression over 4 years of treatment in patients with psoriatic arthritis","volume":"76","author":"Van Der Heijde","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD013614.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s10067-018-4227-7","article-title":"Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial","volume":"37","author":"Walsh","year":"2018","journal-title":"Clinical Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD013614.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s10067-018-4311-z","article-title":"Erratum: correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial (Clinical Rheumatology)","volume":"37","author":"Walsh","year":"2018","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0174|cit174","first-page":"40","article-title":"A randomized, double-blind, active-and placebo (PBO)controlled phase 3 study of efficacy and safety of ixekizumab (IXE), adalimumab (ADA), and placebo therapy in patients na- ive to biologic disease-modifying antirheumatic drugs (bDMARDs) with active psoriatic arthritis (PsA)","volume":"57","author":"Burkhardt","year":"2016","journal-title":"Australasian Journal of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0175|cit175","first-page":"23","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1)","volume":"98","author":"Chandran","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/annrheumdis-2018-eular.2137","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: three year results from a phase 3 study (SPIRIT-P1)","volume":"77","author":"Chandran","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0177|cit177","first-page":"1","article-title":"Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"0","author":"Chandran","year":"2020","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0178|cit178","first-page":"32","article-title":"Effect of concomitant conventional disease-modifying antirheumatic drug (cDMARDS) on safety and efficacy of ixekizumab in biologic dmard (bDMARD) naive patients with active psoriatic arthritis (PsA)","volume":"30","author":"Coates","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/annrheumdis-2016-eular.1399","article-title":"Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis","volume":"75","author":"Coates","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2016-eular.1397","article-title":"Ixekizumab provides sustained improvement up to 52 weeks of disease activity as assessed by composite measure scores in biologic disease-modifying antirheumatic drug (BDMARD)-naive patients with active psoriatic arthritis","volume":"75","author":"Coates","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0181|cit181","first-page":"2110","article-title":"Ixekizumab provides sustained improvement up to 52 weeks of disease activity as assessed by composite measure scores in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0182|cit182","unstructured":"A Study of Ixekizumab in Participants With Active Psoriatic Arthritis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-002326-49-NL 2013"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0183|cit183","first-page":"1841","article-title":"Sustained improvements in physical function, quality of life, and work productivity after ixekizumab therapy in patients with active psoriatic arthritis: 3-year results","volume":"70","author":"Fleischmann","year":"2018","journal-title":"Arthritis and Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0184|cit184","first-page":"924","article-title":"Ixekizumab provides improvements through 52 weeks in physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis","volume":"44","author":"Gottlieb","year":"2017","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0185|cit185","first-page":"2108","article-title":"Effect of concomitant conventional disease-modifying antirheumatic drugs (DMARDs) on the efficacy and safety of ixekizumab in biologic DMARD-naive patients with active psoriatic arthritis","volume":"68","author":"Gottlieb","year":"2016","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0186|cit186","first-page":"4","article-title":"Ixekizumab provides improvements through 52 weeks in physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug (bDMARD) naive patients with active psoriatic arthritis (PsA)","volume":"30","author":"Gottlieb","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0187|cit187","first-page":"345","article-title":"Ixekizumab provides improvements through 52 weeks in physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis","volume":"75","author":"Gottlieb","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0188|cit188","first-page":"2111","article-title":"Ixekizumab provides improvements through 52 weeks in physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis","volume":"68","author":"Gottlieb","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"AB257","DOI":"10.1016\/j.jaad.2016.02.997","article-title":"Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis","volume":"74","author":"Gottlieb","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013614.pub2-BIB0190|cit190","first-page":"2571","article-title":"Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis","volume":"67","author":"Gottlieb","year":"2015","journal-title":"Arthritis and Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"1777-88","DOI":"10.1093\/rheumatology\/key161","article-title":"Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-na\u00efve patients with active psoriatic arthritis (SPIRIT-P1)","volume":"57","author":"Gottlieb","year":"2018","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0192|cit192","first-page":"Abstract Number","article-title":"Ixekizumab provides sustained improvement in signs and symptoms in patients with active psoriatic arthritis: two year results from a phase 3 trial","volume":"69","author":"Helliwell P","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0193|cit193","first-page":"42","article-title":"Ixekizumab provides sustained improvement in signs and symptoms in patients with active psoriatic arthritis: results from a phase 3 trial","volume":"59","author":"Helliwell","year":"2018","journal-title":"Australasian Journal of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0194|cit194","first-page":"44-45","article-title":"Efficacy and safety of ixekizumab at week 52 in biologic-na\u00efve patients with active psoriatic arthritis (SPIRIT-P1)","volume":"47","author":"Lespessailles","year":"2018","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0195|cit195","first-page":"iii115-iii116","article-title":"Efficacy and safety of ixekizumab at week 52 in biologic na\u00efve patients with active psoriatic arthritis (SPIRIT-P1)","volume":"57","author":"Lespessailles","year":"2018","journal-title":"Rheumatology (United Kingdom)"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0196|cit196","first-page":"925","article-title":"52-Week efficacy and safety results from SPIRIT-P1: A phase 3 study of ixekizumab in patients with active psoriatic arthritis","volume":"44","author":"Mease","year":"2017","journal-title":"Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/j.jid.2017.07.592","article-title":"Fifty-two-week efficacy and safety results from SPIRIT-P1: a Phase 3 study of ixekizumab in patients with active psoriatic arthritis","volume":"137","author":"Mease","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0198|cit198","first-page":"32","article-title":"Fifty-two-week efficacy and safety results from SPIRIT-P1: a Phase 3 study of ixekizumab in patients with active psoriatic arthritis","volume":"30","author":"Mease","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0199|cit199","first-page":"6S","article-title":"A Randomized, Double-blind, Active-and Placebo (PBO)-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab (IXE), Adalimumab (ADA), and Placebo Therapy in Patients Na\u00efve to Biologic Disease-modifying Antirheumatic Drugs (bDMARDs) with Active Psoriatic Arthritis (PsA)","volume":"146","author":"Mease","year":"2016","journal-title":"Swiss Medical Weekly"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0200|cit200","first-page":"1169","article-title":"A randomized, double-blind, active- and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients na\u00efve to biologic disease modifying antirheumatic drugs with active psoriatic arthritis","volume":"43","author":"Mease","year":"2016","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"AB248","DOI":"10.1016\/j.jaad.2016.02.967","article-title":"Efficacy of ixekizumab in patients with psoriatic arthritis: results of a phase 3 randomized, double-blind, active-and placebo-controlled study","volume":"74","author":"Mease","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2016-eular.1172","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52 week results from a phase 3 study (spirit-P1)","volume":"75","author":"Mease","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.39700","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52 week results from a phase 3 study","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013614.pub2-BIB0204|cit204","first-page":"1277","article-title":"A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis and Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0206|cit206","first-page":"2178","article-title":"Sustained efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis","volume":"68","author":"Papp","year":"2016","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0207|cit207","first-page":"727","article-title":"Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab for up to 3 years","volume":"70","author":"Van der Heijde","year":"2018","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"Van der Heijde","year":"2018","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0209|cit209","first-page":"S28","article-title":"Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks","volume":"11","author":"Van der Heijde","year":"2018","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/annrheumdis-2017-eular.2221","article-title":"Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks","volume":"76","author":"Van der Heijde","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0211|cit211","article-title":"Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks","volume":"69","author":"Van der Heijde","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0212|cit212","first-page":"998","article-title":"Tofacitinib treatment in patients with psoriatic arthritis and rates of radiologic progression according to baseline CRP levels: results from a phase 3 clinical study","volume":"45","author":"Gladman","year":"2018","journal-title":"Journal of Rheumatology"},{"issue":"16","key":"10.1002\/14651858.CD013614.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1537-50","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0214|cit214","first-page":"AB114","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs: OPAL Broaden, a randomized, placebo-controlled, phase 3 trial","volume":"76","author":"Mease","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"141-2","DOI":"10.1136\/annrheumdis-2017-eular.1416","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs): a randomised, placebo-controlled, phase 3 trial","volume":"76","author":"Mease","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0216|cit216","first-page":"3975","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic DMARDS: a randomized, placebo-controlled, phase 3 trial","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0217|cit217","unstructured":"Efficacy and safety of tofacitinib in psoriatic arthritis: comparator study https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01877668 2013"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0218|cit218","unstructured":"A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-003558-15-ES 2015"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0219|cit219","first-page":"2151","article-title":"ABT-122, an immunoglobulin targeting both TNF-\u03b1 and IL-17a, does not provide significantly greater efficacy compared with adalimumab in subjects with psoriatic arthritis: results from exposure-response analyses","volume":"68","author":"Klunder","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0220|cit220","first-page":"1268-70","article-title":"Safety and efficacy of ABT-122, a TNF and IL-17-targeted dual variable domain (DVD)-IgTM, in psoriatic arthritis patients with inadequate response to methotrexate: results from a phase 2 trial","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor - and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0222|cit222","unstructured":"A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) https:\/\/clinicaltrials.gov\/show\/NCT02349451 2015"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0223|cit223","unstructured":"A study comparing the use of etanercept and methotrexate, used either alone or in combination for the treatment of Psoriatic Arthritis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-004869-24-LV 2015"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0225|cit225","first-page":"161","article-title":"Etanercept and methotrexate as monotherapy or in combination in patients with psoriatic arthritis: a phase 3, double- blind, randomized controlled study","volume":"4","author":"Mease","year":"2019","journal-title":"Journal of Psoriasis and Psoriatic Arthritis"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0226|cit226","unstructured":"Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis https:\/\/clinicaltrials.gov\/show\/NCT02376790 2015"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0227|cit227","unstructured":"Comparison of Ixekizumab with Adalimumab in Patients with Psoriatic Arthritis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2017\/09\/009850 2017"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0228|cit228","unstructured":"A Study of Ixekizumab Versus Adalimumab in Participants With Psoriatic Arthritis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-004585-25-SE 2017"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013614.pub2-BIB0229|cit229","first-page":"3752","article-title":"The effect of ixekizumab versus adalimumab on individual components of the acr composite score, with and without concomitant methotrexate or other conventional synthetic DMARDs at 52 weeks in patients with psoriatic arthritis","volume":"73","author":"Husni","year":"2021","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013614.pub2-BIB0230|cit230","first-page":"322022","article-title":"The effect of ixekizumab versus adalimumab on individual components of the ACR composite score, with and without concomitant methotrexate or other conventional synthetic DMARDS at 52 weeks in patients with psoriatic arthritis","volume":"52","author":"Husni","year":"2022","journal-title":"Internal Medicine Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013614.pub2-BIB0231|cit231","first-page":"i1512022","article-title":"The effect of ixekizumab versus adalimumab on individual components of the ACR composite score, with and without concomitant methotrexate or other conventional synthetic DMARDS, at 52 weeks in patients with psoriatic arthritis","volume":"61","author":"Kiprianos","year":"2022","journal-title":"Rheumatology (United Kingdom)"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0232|cit232","first-page":"30","article-title":"Time to achieve minimal disease activity for ixekizumab versus adalimumab in patients with psoriatic arthritis: posthoc analysis of SPIRIT-H2H","volume":"50","author":"Kristensen","year":"2023","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"261-2","DOI":"10.1136\/annrheumdis-2019-eular.8709","article-title":"Multicentre, randomised, open-label, assessor-blinded, parallel-group head-to-head comparison of the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biologic disease-modifying anti-rheumatic drugs: 24-week","volume":"78","author":"Mease","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"AB1772022","DOI":"10.1016\/j.jaad.2022.06.741","article-title":"Ixekizumab treatment response: consistency over time and at each visit in psoriatic arthritis","volume":"87","author":"Merola","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0236|cit236","unstructured":"A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03151551 2017"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0237|cit237","first-page":"e20221042022","article-title":"Efficacy and safety of ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H Trial","volume":"12","author":"Reich","year":"2022","journal-title":"Dermatology Practical & Conceptual"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"Journal of Dermatological Science"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-019-1998-4","article-title":"Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial","volume":"21","author":"De Jong","year":"2019","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0240|cit240","unstructured":"A randomized, double-blind, placebo-controlled trial of golimumab+methotrexate versus methotrexate alone in methotrexate-na\u00efve patients with psoriatic arthritis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2012-005214-19-NL 2013"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0241|cit241","unstructured":"Initial Treatment With Golimumab in Early PsA https:\/\/clinicaltrials.gov\/show\/NCT01871649 2013"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0242|cit242","first-page":"1835","article-title":"Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomized, placebo-controlled trial of golimumab + methotrexate versus placebo + methotrexate","volume":"70","author":"Van Mens","year":"2018","journal-title":"Arthritis & Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","article-title":"Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate","volume":"78","author":"Van Mens","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0244|cit244","unstructured":"Golimumab efficacy in psoriatic arthritis patients with active dactylitis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-000643-40-PT 2013"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0245|cit245","unstructured":"Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx na\u00efve Psoriatic Arthritis Patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02065713 2014"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"490-8","DOI":"10.1136\/annrheumdis-2019-216500","article-title":"GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis","volume":"79","author":"Vieira-Sousa","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/annrheumdis-2019-eular.5164","article-title":"GO-DACT: a randomized double-blind placebocontroled proof-of-concept trial of golimumab plus methotrexate (MTX) versus mtx monotherapy, in improving dactylitis, in MTX naive psoriatic arthritis patients","volume":"78","author":"Vieira-Sousa","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0248|cit248","first-page":"80","article-title":"The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy","volume":"43","author":"Vieira-Sousa","year":"2018","journal-title":"Acta Reumatologica Portuguesa"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/annrheumdis-2017-eular.5462","article-title":"The GO-DACT protocol: a randomized controlled trial to compare the efficacy of golimumab in combination with methotrexate (MTX) versus mtx monotherapy, in improving dactylitis and enthesitis, in MTX na\u00efve psoriatic arthritis patients","volume":"76","author":"Vieira-Sousa","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","article-title":"Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II\/III randomized controlled study","volume":"37","author":"Asahina","year":"2010","journal-title":"Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/ard.2010.130864","article-title":"Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study","volume":"70","author":"Atzeni","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"AB33","DOI":"10.1016\/j.jaad.2017.04.148","article-title":"Adalimumab improves health-related quality of life in patients with fingernail psoriasis","volume":"76","author":"Augustin","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. Methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0254|cit254","unstructured":"Euctr B E An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2005-000085-39-BE 2006"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0255|cit255","unstructured":"The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00251641 2005"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1507-1514","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0257|cit257","first-page":"1265","article-title":"Secukinumab demonstrates sustained high efficacy and a favorable safety profile in moderate to severe psoriasis patients through 4 years of treatment (extension of sculpture study)","volume":"56","author":"Bissonnette","year":"2017","journal-title":"International Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/annrheumdis-2018-eular.5825","article-title":"Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: Phase 3 voyage 1 trial","volume":"77","author":"Griffiths C","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"AB83","DOI":"10.1016\/j.jaad.2017.04.338","article-title":"Consistency of response across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials","volume":"76","author":"Blauvelt","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0261|cit261","first-page":"207","article-title":"Adalimumab has no significant effect on interleukin-17 and interleukin-17 receptor expression in skin and synovium of psoriatic arthritis patients with mild psoriasis","volume":"6","author":"Bolt","year":"2021","journal-title":"Journal of psoriasis and psoriatic arthritis"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0262|cit262","first-page":"26S","article-title":"Safety profile of upadacitinib up to 3 years in patients with psoriatic arthritis: an integrated analysis from the phase 3 program","volume":"151(SUPPL 252)","author":"Burmester Gerd","year":"2021","journal-title":"Swiss medical weekly"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/annrheumdis-2016-eular.4343","article-title":"Efficacy and safety of golimumab in patients with active, very early peripheral spondyloarthritis: First results from the CRESPA study, a monocentric, placebo-controlled randomized trial","volume":"75","author":"Carron","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/annrheumdis-2016-210775","article-title":"Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study","volume":"76","author":"Carron","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0265|cit265","unstructured":"An open randomized controlled trial of Upadacitinib to improve anxiety in patients with psoriatic arthritis trialsearch.who.int 2024 Trial ID: ChiCTR2400079755"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0266|cit266","first-page":"2571","article-title":"ADalimumab for Psoriatic arthritis: Improvement in Psoriasis is associated with long-term inhibition of radiographic progression","volume":"36","author":"Choy E H","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0267|cit267","first-page":"i56","article-title":"In patients with psoriatic arthritis receiving adalimumab, improvement in psoriasis is associated with long-term inhibition of radiographic progression","volume":"48","author":"Choy","year":"2009","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0268|cit268","first-page":"2022","article-title":"Achieving minimal disease activity (MDA) criteria with anti-TNF therapy in psoriatic arthritis can prevent progressive joint damage","volume":"60","author":"Coates L","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0269|cit269","first-page":"i17","article-title":"Achieving minimal disease activity criteria with anti-TNF therapy in psoriatic arthritis can prevent progressive joint damage","volume":"49","author":"Coates L","year":"2010","journal-title":"Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates L","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0271|cit271","first-page":"2916","article-title":"Long-term inhibition of radiographic progression with originator adalimumab in patients with moderate to severe psoriatic arthritis with or without radiographic damage at baseline","volume":"70","author":"Coates L","year":"2018","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0272|cit272","first-page":"2715-2718","article-title":"The performance characteristics of composite measures used in a randomized trial examining etanercept and methotrexate as monotherapy or in Combination in Patients with Psoriatic Arthritis","volume":"71","author":"Coates","year":"2019","journal-title":"Arthritis & rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"33-","DOI":"10.1136\/annrheumdis-2020-eular.2393","article-title":"Adalimumab introduction versus methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis: results from randomized phase 4 control study","volume":"79(SUPPL 1)","author":"Coates L","year":"2020","journal-title":"Annals of the rheumatic diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0274|cit274","first-page":"1301-1302","article-title":"Ixekizumab treatment response: consistency over time and at each visit in psoriatic arthritis","volume":"80(SUPPL 1)","author":"Coates L","year":"2021","journal-title":"Annals of the rheumatic diseases"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/acr.24442","article-title":"Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab","volume":"74","author":"Coates L","year":"2022","journal-title":"Arthritis care & research"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3899\/jrheum.151290","article-title":"Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials","volume":"43","author":"Combe","year":"2016","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/ard.2009.119446","article-title":"Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis","volume":"69","author":"D'Angelo","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/bjd.14867","article-title":"A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study","volume":"176","author":"Vries A C","year":"2017","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/annrheumdis-2013-eular.313","article-title":"Clinical and imaging efficacy of etanercept in early non-radiographic axial spondyloarthritis: A 12-week, randomized, double-blind, placebo-controlled trial","volume":"72","author":"Dougados","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0281|cit281","unstructured":"Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes (EMBARK) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01258738 2010"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0282|cit282","first-page":"2648","article-title":"The effect of tofacitinib on residual pain in patients with psoriatic arthritis","volume":"71","author":"Dougados","year":"2019","journal-title":"Arthritis and rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0283|cit283","first-page":"AB204","article-title":"Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis","volume":"76","author":"Elewski","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0284|cit284","doi-asserted-by":"crossref","unstructured":"Elewski BE Rich PA Behrens F Guillet G Geng Z Servin OR Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis Acta Dermato-Venereologica 2018 26 7","DOI":"10.1136\/annrheumdis-2017-eular.2148"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"AB201","DOI":"10.1016\/j.jaad.2019.06.741","article-title":"Efficacy of adalimumab in nail psoriasis by history of psoriatic arthritis and overall safety from final, open-label 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"81","author":"Elewski","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/annrheumdis-2017-eular.1969","article-title":"The effect of certolizumab pegol on extra-articular manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior anti-TNF exposure","volume":"76","author":"Fitz Gerald","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0288|cit288","unstructured":"Etanercept efficacy for psoriatic arthritis sustained at 2 years Formulary 2004 39 2 74"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0289|cit289","first-page":"A55","article-title":"Results of a randomized, double-blind study to evaluate the efficacy and safety of etanercept in patients with psoriasis and psoriasis and psoriatic arthritis: The presta trial","volume":"39","author":"Freundlich","year":"2009","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0290|cit290","first-page":"S242","article-title":"Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients: 24 week patient reported outcome results of a phase 3 double blind randomized placebo-controlled study","volume":"64","author":"Gladman D","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/ard.2003.018085","article-title":"Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis","volume":"63","author":"Goedkoop A","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"AB262","DOI":"10.1016\/j.jaad.2019.06.1151","article-title":"Rapid and sustained improvements in cutaneous and musculoskeletal signs and symptoms with 108 weeks treatment of ixekizumab in psoriatic arthritis in biologic-naive and TNF-inadequate responder patients","volume":"81","author":"Gottlieb","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0293|cit293","first-page":"S17","article-title":"A phase 3 trial comparing ixekizumab with placebo and etanercept for moderate-to-severe plaque psoriasis: Results from the 12 week induction period of UNCOVER-2","volume":"135","author":"Griffiths C","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013614.pub2-BIB0294|cit294","article-title":"Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis","volume":"69","author":"Helliwell P","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"379-380","DOI":"10.1136\/annrheumdis-2018-eular.1275","article-title":"Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis","volume":"77","author":"Helliwell","year":"2018","journal-title":"Annals of the rheumatic diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0296|cit296","first-page":"2715","article-title":"What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: comparison of Treatment Effects in the SEAM-PsA Trial","volume":"72 (SUPPL 10)","author":"Helliwell","year":"2020","journal-title":"Arthritis & rheumatology"},{"issue":"1-2","key":"10.1002\/14651858.CD013614.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.autneu.2008.05.005","article-title":"Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis","volume":"143","author":"Holman A","year":"2008","journal-title":"Auton Neurosci"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0298|cit298","first-page":"S99-","article-title":"Ixekizumab demonstrates improvement comparable to adalimumab across acr components in biologic-nave patients with psoriatic arthritis","volume":"20(3 SUPPL 1)","author":"Husni M","year":"2020","journal-title":"Journal of clinical rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0299|cit299","unstructured":"A pilot study for the effect of infliximab on endothelial function in patients with psoriasis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000027208 2017"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety Results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0301|cit301","first-page":"S697","article-title":"Value and prediction of minimal disease activity in patients with psoriatic arthritis","volume":"66","author":"Kavanaugh","year":"2014","journal-title":"Arthritis and Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/acr.22576","article-title":"Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study","volume":"68","author":"Kavanaugh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"767-","DOI":"10.1136\/annrheumdis-2020-eular.3996","article-title":"Head-to-head study evaluating the combined ACR50\/PASI100 treatment response of ixekizumab versus adalimumab: individual patient data from a randomized, openlabel study in biologic-naive patients with psoriatic arthritis through week 52","volume":"79(SUPPL 1)","author":"Kavanaugh","year":"2020","journal-title":"Annals of the rheumatic diseases"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/key312","article-title":"Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis","volume":"58","author":"Khatri","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0305|cit305","first-page":"S19","article-title":"Ixekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis","volume":"135","author":"Kimball A","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0306|cit306","unstructured":"[Aldalimumab in psoriatic arthritis and as the initial therapy in rheumatoid arthritis] Krankenpflege Journal 2005 43 7-10 244 16515313"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0307|cit307","first-page":"S6","article-title":"Efficacy of ixekizumab in patients with and without previous experience with biologic therapies compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with plaque psoriasis","volume":"135","author":"Lacour J","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0308|cit308","first-page":"1819-1822","article-title":"Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study","volume":"72(SUPPL 10)","author":"McInnes","year":"2020","journal-title":"Arthritis & rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"AB178","DOI":"10.1016\/j.jaad.2008.11.774","article-title":"The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis","volume":"60","author":"Mease","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease P","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0311|cit311","first-page":"S31","article-title":"Therapeutic response in adalimumab-treated patients with psoriatic arthritis in relation to weight","volume":"135","author":"Mease","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/annrheumdis-2016-eular.3205","article-title":"Improvements in joint outcomes of psoriatic arthritis over 4 years of treatment with certolizumab pegol in patients with and without prior anti-TNF exposure","volume":"75","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0313|cit313","first-page":":79","article-title":"Mease, P. J.; Van Der Heijde, D.; Ritchlin, C. T.; Okada, M.; Cuchacovich, R. S.; Shuler, C. L.; Lin, C. Y.; Braun, D. K.; Lee, C. H.; Gladman, D. D.","volume":"76","author":"for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/annrheumdis-2019-eular.180","article-title":"Inhibition of radiographic progression was achieved with intravenous golimumab in active psa patients regardless of changes in composite indices of disease activity in a phase III trial","volume":"78","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0315|cit315","first-page":"S67","article-title":"Inhibition of radiographic progression and correlation with changes in composite disease activity indices in patients with active psoriatic arthritis treated with intravenous golimumab, as measured in a phase III trial","volume":"25","year":"2019","journal-title":"Journal of Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"e007394","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of two psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circulation Cardiovascular Imaging"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0317|cit317","doi-asserted-by":"crossref","unstructured":"Wan MT Noe MH Shin DB Armstrong AW Duffin KC Chiesa Fuxench ZC The vascular inflammation in psoriasis (VIP) trial: a secondary analysis of patient reported outcomes for patients treated with adalimumab, phototherapy, or placebo Journal of Investigative Dermatology 2019 S93","DOI":"10.1016\/j.jid.2019.03.614"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0318|cit318","first-page":"AB160","article-title":"Health-related quality of life outcomes in patients with moderate to severe psoriasis treated with ABT-874 versus etanercept or placebo","volume":"64","author":"Menter","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0319|cit319","first-page":"2627","article-title":"Improvement in the signs and symptoms of psoriatic arthritis with ixekizumab compared to adalimumab in patient subgroups defined by baseline disease characteristics","volume":"71","author":"Merola","year":"2019","journal-title":"Arthritis and rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"1855-1856","DOI":"10.1136\/annrheumdis-2019-eular.183","article-title":"Efficacy of Guselkumab in psoriasis patients with self-reported psoriatic arthritis with involvement of the scalp, nails, hands, and feet: a pooled analysis from 2 pivotal phase 3 psoriasis studies","volume":"78","author":"Merola J","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD013614.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1111\/jdv.16433","article-title":"Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies","volume":"34","author":"Merola J","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-018-0106-6","article-title":"Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0323|cit323","unstructured":"A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis https:\/\/clinicaltrials.gov\/show\/NCT00106834 2005"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0324|cit324","unstructured":"Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis https:\/\/clinicaltrials.gov\/show\/NCT00195689 2005"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0325|cit325","unstructured":"BI 655066 (risankizumab) compared to active comparator (adalimumab) in patients with moderate to severe chronic plaque psoriasis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2015-003623-65-CZ 2016"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0326|cit326","unstructured":"Safety and Efficacy Study of Etanercept (Qiangke\u00ae) to Treat Moderate to Severe Plaque Psoriasis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02701205 2016"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0327|cit327","unstructured":"A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02814175 2016"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0328|cit328","unstructured":"A study of subjects with Psoriatic Arthritis to investigate the effectiveness of adalimumab introduction compared with methotrexate dose escalation http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-000191-21-GB 2016;(): 2016"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0329|cit329","first-page":"2594-2595","article-title":"Multi-symptom impact on the EQ5D index in bio-naive active psoriatic arthritis patients: an analysis through week 24 of the go-vibrant study","volume":"71","author":"Ogdie","year":"2019","journal-title":"Arthritis & rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"AB246","DOI":"10.1016\/j.jaad.2016.02.962","article-title":"Effects of adalimumab on health-related quality of life in psoriasis patients with and without comorbid psoriatic arthritis: Value of reducing PASI scores and systemic inflammation","volume":"74","author":"Okun","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0331|cit331","first-page":"54","article-title":"Effect of tildrakizumab on personal relationships in patients with moderate-to-severe chronic plaque psoriasis","volume":"98","author":"Papp","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"AB252","DOI":"10.1016\/j.jaad.2017.04.979","article-title":"The effects of age, gender, weight, age at onset, psoriasis severity, nail involvement, and presence of psoriatic arthritis at baseline on the efficacy of ixekizumab in patients with moderate-tosevere psoriasis","volume":"76","author":"Praiser","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0333|cit333","first-page":"2861","article-title":"Impact of guselkumab versus placebo and adalimumab on patient reported outcomes in patients with and without psoriatic arthritis in a phase 3 pivotal psoriasis study","volume":"70","author":"Puig","year":"2018","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0334|cit334","first-page":"50","article-title":"Impact of guselkumab versus placebo and adalimumab on patient reported outcomes in patients with and without psoriatic arthritis in voyage 2","volume":"98","author":"Puig","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kew204","article-title":"Reduced CLEC9A expression in synovial tissue of psoriatic arthritis patients after adalimumab therapy","volume":"55","author":"Ramos M","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0336|cit336","first-page":"S35","article-title":"Ixekizumab impact on health-related quality of life compared to etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque psoriasis","volume":"135","author":"Reich","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0337|cit337","unstructured":"Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis https:\/\/clinicaltrials.gov\/show\/NCT01690299 2012"},{"issue":"suppl 10)","key":"10.1002\/14651858.CD013614.pub2-BIB0338|cit338","article-title":"Efficacy and safety of apremilast through 104 weeks in subjects with moderate to severe psoriasis randomized to placebo, apremilast, or etanercept who continued on or switched to apremilast after week 16 in a phase 3B study","volume":"69","author":"Reich","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/annrheumdis-2017-eular.5163","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment in the liberate study","volume":"76","author":"Reich","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2016-eular.1732","article-title":"52-Week efficacy and safety of apremilast and switch from etanercept in patients with moderate to severe psoriasis: Results from the liberate study","volume":"75","author":"Reich","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0341|cit341","first-page":"2113","article-title":"Efficacy and safety of apremilast and switch from etanercept in patients with moderate to severe psoriasis: 52-week results","volume":"68","author":"Reich","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"AB124","DOI":"10.1016\/j.jaad.2009.11.474","article-title":"Adalimumab response is consistent across subgroups of patients with moderate to severe psoriasis: Subanalysis of the CHAMPION study","volume":"62","author":"Saurat J","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013614.pub2-BIB0344|cit344","first-page":"3487","article-title":"The majority of patients with moderate to severe psoriatic arthritis had existing structural damage, predisposing them to further progression, which was markedly inhibited by adalimumab","volume":"67","author":"Sheth","year":"2015","journal-title":"Arthritis and rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0346|cit346","first-page":"1","article-title":"Clinical and MRI remission in patients with non radiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial","volume":"20","author":"Heijde","year":"2018","journal-title":"Arthritis Research and Therapy"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0347|cit347","first-page":"64","article-title":"Effect of secukinumab on psoriasis symptoms and physical functioning compared with placebo and etanercept in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: A subanalysis from the phase 3 fixture study","volume":"43","author":"Sigurgeirsson","year":"2014","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"AB109","DOI":"10.1016\/j.jaad.2017.04.434","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: Results from two phase 3 studies","volume":"76","author":"Strand","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013614.pub2-BIB0349|cit349","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: results from 2 phase 3 studies","volume":"69","author":"Strand","year":"2017","journal-title":"Arthritis & rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0351|cit351","first-page":"AB160","article-title":"Health-related quality of life in patients with moderate to severe psoriasis: Effects of treatment with ABT-874 versus etanercept or placebo","volume":"64","author":"Crowley","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Strober","year":"2011","journal-title":"The British Journal of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0353|cit353","first-page":"7S-","article-title":"Comparative effects of ixekizumab vs adalimumab across psori-atic arthritis patients defined by baseline characteristics: week 24 outcomes from SPIRIT-H2H","volume":"150(SUPPL 245)","author":"Tahir","year":"2020","journal-title":"Swiss medical weekly"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"AB158","DOI":"10.1016\/j.jaad.2010.09.644","article-title":"Joint pain improvement in patients on etanercept therapy for moderate to severe psoriasis","volume":"64","author":"Tyring","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13555-021-00520-0","article-title":"Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results","volume":"11","author":"Umezawa","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013614.pub2-BIB0356|cit356","article-title":"Tofacitinib treatment in patients with psoriatic arthritis and rates of radiologic progression according to baseline crp levels: Results from a phase 3 clinical study","volume":"69","author":"Van Der Heijde","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"1027-","DOI":"10.1136\/annrheumdis-2018-eular.2637","article-title":"Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years' treatment","volume":"77","author":"Van Der Heijde","year":"2018","journal-title":"Annals of the rheumatic diseases"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3899\/jrheum.180971","article-title":"Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab","volume":"46","author":"Heijde","year":"2019","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"1266-","DOI":"10.1136\/annrheumdis-2019-eular.5164","article-title":"GO-DACT: a randomized double-blind placebocontroled proof-of-concept trial of golimumab plus methotrexate (MTX) versus MTX monotherapy, in improving dactylitis, in MTX na\u00c3\u00afve psoriatic arthritis patients","volume":"78","author":"Vieira-Sousa","year":"2019","journal-title":"Annals of the rheumatic diseases"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"AB253","DOI":"10.1016\/j.jaad.2017.04.984","article-title":"The efficacy of certolizumab pegol over 4 years in psoriatic arthritis patients with and without concomitant use of DMARDs","volume":"76","author":"Walsh","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD013614.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s10067-018-4311-z","article-title":"Erratum: correction to: efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial","volume":"37","year":"2018","journal-title":"Clinical rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"AB232","DOI":"10.1016\/j.jaad.2015.02.937","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebocontrolled, double-blind Study","volume":"72","author":"Zhang","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0364|cit364","first-page":"26442022","article-title":"Biologics improve endothelial, vascular and left ventricular myocardial function in patients with psoriatic arthritis","volume":"60","author":"Ikonomidis","year":"2022","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0365|cit365","unstructured":"An investigator-initiated double-blind, parallel-group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes: the GOLMePsA study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-004122-28\/GB 2015"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12891-017-1659-1","article-title":"The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of golimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes","volume":"18","author":"De Marco","year":"2017","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0367|cit367","unstructured":"GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA) https:\/\/clinicaltrials.gov\/show\/NCT04108468 2019"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0368|cit368","unstructured":"A stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug free remission in psoriatic arthritis (PsA). TOFA-PREDICT http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2017-003900-28-NL 2018"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"e0643382022","DOI":"10.1136\/bmjopen-2022-064338","article-title":"TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA)","volume":"12","author":"Kleinrensink","year":"2022","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0370|cit370","unstructured":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis https:\/\/clinicaltrials.gov\/show\/NCT03445845 2018"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0371|cit371","unstructured":"A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-001996-35-HU 2020"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0372|cit372","unstructured":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy https:\/\/clinicaltrials.gov\/show\/NCT04115748 2019"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0373|cit373","unstructured":"A Study of the Efficacy and Safety of Guselkumab and Golimumab in Participants with Active Psoriatic Arthritis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-002012-31-ES 2021"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0374|cit374","unstructured":"A study of guselkumab and golimumab combination therapy in participants with active psoriatic arthritis https:\/\/clinicaltrials.gov\/show\/NCT05071664 2021"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0375|cit375","unstructured":"Evaluation of sonelokimab in patients with active psoriatic arthritis https:\/\/www.who.int; https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-005947-58\/HU"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0376|cit376","unstructured":"Evaluation of sonelokimab for the treatment of patients with active psoriatic arthritis https:\/\/clinicaltrials.gov\/study\/NCT05640245"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0377|cit377","unstructured":"Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients https:\/\/clinicaltrials.gov\/show\/NCT05669833 2022"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/annrheumdis-2023-eular.876","article-title":"Guselkumab vs golimumab in PsA TNFi inadequate responders (Evolution): formulating a pragmatic phase 3b randomized trial","volume":"82","author":"Ogdie","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"e078539","DOI":"10.1136\/bmjopen-2023-078539","article-title":"Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis","volume":"13","author":"Ooms","year":"2023","journal-title":"BMJ Open"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/art.22800","article-title":"Improved survival in psoriatic arthritis with calendar time","volume":"56","author":"Ali","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"e003064","DOI":"10.1136\/rmdopen-2023-003064","article-title":"Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies","volume":"9","author":"Aureal","year":"2023","journal-title":"RMD Open"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1359-6101(01)00020-X","article-title":"Tumor necrosis factor or tumor promoting factor?","volume":"13","author":"Balkwill","year":"2002","journal-title":"Cytokine and Growth Factor Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","article-title":"Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry","volume":"9","author":"Bobbio Pallavicini","year":"2010","journal-title":"Autoimmunity Reviews"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systemic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The Premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Research and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"4","author":"Carmona","year":"2011","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.10245","article-title":"Fatigue in cancer patients compared with fatigue in the general United States population","volume":"94","author":"Cella","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0393|cit393","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"936\u20139","DOI":"10.1136\/ard.2006.065763","article-title":"Functional Assessment of Chronic Illness Therapy - Fatigue Scale is valid in patients with psoriatic arthritis","volume":"66","author":"Chandran","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2133.2007.08148.x","article-title":"Psoriasis and psoriatic arthritis: separate or one and the same?","volume":"157","author":"Ciocon","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD013614.pub2-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a department of veterans affairs cooperative study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0397|cit397","first-page":"1438","article-title":"Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review","volume":"35","author":"Coates","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/ard.2007.082925","article-title":"Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience","volume":"67","author":"Coates","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0400|cit400","first-page":"1251","article-title":"New GRAPPA and EULAR recommendations for the management of psoriatic arthritis","volume":"56","author":"Coates","year":"2017","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1874312901105010133","article-title":"Synovial tissue response to treatment in psoriatic arthritis","volume":"5","author":"Codullo","year":"2011","journal-title":"Open Rheumatology Journal"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/OARRR.S56073","article-title":"Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders","volume":"9","author":"D'Angelo","year":"2017","journal-title":"Open Access Rheumatology: Research and Reviews"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0403|cit403","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti\u2013tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clinical and Experimental Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register","volume":"58","author":"Fagerli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14728222.12.9.1085","article-title":"Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis","volume":"12","author":"Fantuzzi","year":"2008","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0411|cit411","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0413|cit413","first-page":"238","article-title":"Severe psoriasis--oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and meta-analyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0416|cit416","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0420|cit420","unstructured":"GRADEpro Guideline Development Tool McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org 2015"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor \u03b1 inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0422|cit422","first-page":"1302","article-title":"Measuring dactylitis in clinical trials: which is the best instrument to use?","volume":"34","author":"Healy","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis & Rheumatism (Arthritis Care & Research)"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0424|cit424","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0425|cit425","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1093\/rheumatology\/keaa828","article-title":"Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors \u2013 a Nordic cohort study","volume":"60","author":"Hellgren","year":"2021","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0426|cit426","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0428|cit428","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from https:\/\/training.cochrane.org\/es\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0429|cit429","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0430|cit430","first-page":"511\u20137","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.22443","article-title":"A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time?","volume":"56","author":"Husted","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2019-216693","article-title":"Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden","volume":"79","author":"Iskov Kopp","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0433|cit433","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00197452","article-title":"Human tumor necrosis factor increases the resistance against Listeria infection in mice","volume":"178","author":"Kato","year":"1989","journal-title":"Medical Microbiology and Immunology"},{"issue":"39","key":"10.1002\/14651858.CD013614.pub2-BIB0434|cit434","first-page":"S142","article-title":"The assessment of disease activity and outcomes in psoriatic arthritis","volume":"23","author":"Kavanaugh","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"33","key":"10.1002\/14651858.CD013614.pub2-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"(e7833)","DOI":"10.1097\/MD.0000000000007833","article-title":"Characteristics of Turkish patients with elderly onset psoriatic arthritis: a retrospective cohort study","volume":"96","author":"Kobak","year":"2017","journal-title":"Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0439|cit439","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-\u03b1 therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1196\/annals.1351.019","article-title":"Epidemiological aspects of rheumatoid arthritis: the sex ratio","volume":"1069","author":"Kvien","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3899\/jrheum.090832","article-title":"Minimally important difference for patient-reported outcomes in psoriatic arthritis: health assessment questionnaire and pain, fatigue, and global visual analog scale","volume":"37","author":"Kwok","year":"2010","journal-title":"Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety","volume":"34","author":"Lemos","year":"2014","journal-title":"Rheumatology International"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","volume":"53","author":"Lenercept Multiple Sclerosis Study Group","year":"1999","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3899\/jrheum.101256","article-title":"Minimal important difference and responsiveness to change of the SF-36 in patients with psoriatic arthritis receiving tumor necrosis factor-alpha blockers","volume":"38","author":"Leung","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"22","key":"10.1002\/14651858.CD013614.pub2-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3899\/jrheum.17666","article-title":"The sex influence on response to tumor necrosis factor-\u03b1 inhibitors and remission in axial spondyloarthritis","volume":"45","author":"Lubrano","year":"2018","journal-title":"Journal of Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"1052\u20133","DOI":"10.1136\/ard.2007.084897","article-title":"Sex: a major predictor of remission as measured by 28-joint disease activity score (DAS28) in early rheumatoid arthritis?","volume":"67","author":"Makinen","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0450|cit450","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert Review of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0453|cit453","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trial: an evaluation and practitioner\u2019s guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0454|cit454","unstructured":"McDonald S Noel-Storr AH Thomas J Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews Global Evidence Summit, Cape Town, South Africa; 13th \u2013 16th September 2017"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0455|cit455","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/ard.2003.006296","article-title":"Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis","volume":"63","author":"McKenna","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0458|cit458","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.semarthrit.2018.05.010","article-title":"Functional impairment measurement in psoriatic arthritis: Importance and challenges","volume":"48","author":"Mease","year":"2018","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0459|cit459","first-page":"S64","article-title":"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care & Research"},{"issue":"12","key":"10.1002\/14651858.CD013614.pub2-BIB0460|cit460","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0461|cit461","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0463|cit463","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1128\/iai.56.10.2563-2569.1988","article-title":"Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection","volume":"56","author":"Nakane","year":"1988","journal-title":"Infection and Immunity"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0464|cit464","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0465|cit465","unstructured":"Noel-Storr AH Project Transform team Cochrane Crowd: new ways of working together to produce health evidence Evidence Live 2018, Oxford, UK; 18 \u2013 20 June 2018"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0466|cit466","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0467|cit467","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","article-title":"Patient reported outcome in psoriatic arthritis","volume":"42","author":"Orbai","year":"2016","journal-title":"Rheumatic Disease Clinics of North America"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0468|cit468","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3899\/jrheum.160904","article-title":"Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016","volume":"44","author":"Orbai","year":"2017","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0469|cit469","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook\/current\/chapter-13"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0470|cit470","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0471|cit471","first-page":"105","article-title":"Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid","volume":"25","author":"Partsch","year":"1998","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0472|cit472","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10067-014-2652-9","article-title":"Extra-articular manifestations in psoriatic arthritis patients","volume":"34","author":"Peluso","year":"2015","journal-title":"Clinical Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD013614.pub2-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","article-title":"Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire","volume":"26","author":"Pincus","year":"1983","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0474|cit474","unstructured":"PlotDigitizer https:\/\/automeris.io\/WebPlotDigitizer\/ 2025"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0475|cit475","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.58.4.226","article-title":"Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease","volume":"58","author":"Punzi","year":"1999","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD013614.pub2-BIB0476|cit476","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/rheumatology\/37.7.760","article-title":"Radiological assessment in psoriatic arthritis","volume":"37","author":"Rahman","year":"1998","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0478|cit478","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0479|cit479","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD013614.pub2-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","article-title":"Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone","volume":"51","author":"Rosen","year":"2012","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0482|cit482","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2017.11.005","article-title":"TNF inhibitors in rheumatoid arthritis and spondyloarthritis: are they the same?","volume":"17","author":"Rubbert-Roth","year":"2018","journal-title":"Autoimmunity Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0483|cit483","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Research and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register","volume":"49","author":"Saad","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0485|cit485","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0486|cit486","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"13","key":"10.1002\/14651858.CD013614.pub2-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.2741\/3066","article-title":"TNF: a master switch for inflammation to cancer","volume":"1","author":"Sethi","year":"2008","journal-title":"Frontiers in Bioscience"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0488|cit488","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0490|cit490","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD013614.pub2-BIB0491|cit491","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care & Research"},{"issue":"8","key":"10.1002\/14651858.CD013614.pub2-BIB0492|cit492","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0493|cit493","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.22770","article-title":"Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis","volume":"57","author":"Taylor","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/jcm8040515","article-title":"How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?\u2014MTX in the Treat-to-Target Strategy","volume":"8","author":"Taylor","year":"2019","journal-title":"Journal of Clinical Medicine"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0495|cit495","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jclinepi.2017.08.011","article-title":"Living Systematic Reviews: 2. Combining human and machine effort","volume":"91","author":"Thomas","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013614.pub2-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","article-title":"Work disability in psoriatic arthritis: a systematic review","volume":"51","author":"Tillett","year":"2012","journal-title":"Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0497|cit497","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2004.05.007","article-title":"Quantification of radiological damage in inflammatory arthritis: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"18","author":"Van der Heijde","year":"2004","journal-title":"Best Practice & Research Clinical Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0498|cit498","doi-asserted-by":"crossref","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64","author":"Van der Heijde","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism criteria","volume":"39","author":"Van Gestel","year":"1996","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"Van Gestel","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD013614.pub2-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2B","volume":"47","author":"Van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0502|cit502","first-page":"S65","article-title":"The development of the Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS 28)","volume":"32","author":"Van Riel","year":"2014","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD013614.pub2-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"3","key":"10.1002\/14651858.CD013614.pub2-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s003930170064","article-title":"A method to score radiographic change in psoriatic arthritis","volume":"60","author":"Wassenberg","year":"2001","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"4","key":"10.1002\/14651858.CD013614.pub2-BIB0505|cit505","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013614.pub2-BIB0506|cit506","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012722.pub2","article-title":"Methotrexate for psoriatic arthritis","author":"Wilsdon","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013614.pub2-BIB0507|cit507","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013614","article-title":"Tumor necrosis factor (TNF) inhibitors for the treatment of psoriatic arthritis","author":"Cagnotto","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:35:51Z","timestamp":1786030551000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013614.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":507,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013614.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}